CALLABLE KICK-IN GOAL LINKED TO WORST OF - ROCHE GS/NOVARTIS N/BAYER/SIEMENS Stock

Certificat

KNYBDU

CH1256195079

Real-time Bid/Ask 05:56:52 2024-05-27 EDT
55 CHF / 56 CHF -0.54% Intraday chart for CALLABLE KICK-IN GOAL LINKED TO WORST OF - ROCHE GS/NOVARTIS N/BAYER/SIEMENS
Current month+1.45%
1 month+2.29%
Date Price Change
24-05-24 55.8 -0.27%
24-05-23 55.95 -1.84%
24-05-21 57 -0.78%

Delayed Quote Swiss Exchange

Last update May 24, 2024 at 11:20 am

More quotes

Static data

Product typeObligations Convertibles
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
KNYBDU
ISINCH1256195079
Date issued 2023-03-29
Strike 258.8 CHF
Maturity 2025-03-31 (309 Days)
Parity 1 : 1
Emission price 100 CHF
Emission volume N/A
Settlement règlement en espèces
Currency CHF

Technical Indicators

Highest since issue 101.8 CHF
Lowest since issue 53.5 CHF
Spread 10 CHF
Spread %1.79%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
230.4 CHF
Average target price
279.8 CHF
Spread / Average Target
+21.46%
Consensus
  1. Stock Market
  2. Certificates
  3. KNYBDU Certificat